MAP2K7 and uveal melanoma: Although the MEK-inhibitor selumetinib did not improve survival in cutaneous melanoma, when administered to uveal melanoma patients with GNAQ mutation it extended progression-free survival.168,169 The main limitation of MAPK inhibitors is that the drug is effective for an average of 6-10 months and it is believed this leads to more aggressive recurrences.